(VIANEWS) – MONTEA (MONT.BR), NAVAMEDIC (NAVA.OL), MOWI (MOWI.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. MONTEA (MONT.BR)
25.8% sales growth and 5.79% return on equity
Montea NV is a public regulated real estate company under Belgian law (GVV/SIR) that specialises in logistical property in Belgium, the Netherlands, France, and Germany. The company is a benchmark player in this market. Montea literally offers its customers the space to grow through versatile and innovative property solutions. In this way, Montea creates value for its shareholders. As of 30/09/2023 the property portfolio represented a total surface of 1,921,172 m² spread across 94 locations. Montea NV has been listed on Euronext Brussels (MONT) and Euronext Paris (MONTP) since the end of 2006.
Earnings Per Share
As for profitability, MONTEA has a trailing twelve months EPS of €4.22.
PE Ratio
MONTEA has a trailing twelve months price to earnings ratio of 16.8. Meaning, the purchaser of the share is investing €16.8 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.79%.
Sales Growth
MONTEA’s sales growth is 5% for the present quarter and 25.8% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 19, 2023, the estimated forward annual dividend rate is 3.3 and the estimated forward annual dividend yield is 4.73%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MONTEA’s EBITDA is 142.45.
Volume
Today’s last reported volume for MONTEA is 5157 which is 66.67% below its average volume of 15473.
More news about MONTEA.
2. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 11.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 32.63. Meaning, the purchaser of the share is investing kr32.63 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.97%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 13, 2010, the estimated forward annual dividend yield is 11.61%.
More news about NAVAMEDIC.
3. MOWI (MOWI.OL)
12.7% sales growth and 10.75% return on equity
Mowi ASA, a seafood company, produces and supplies farmed salmon products worldwide. It operates through three segments: Feed, Farming, and Sales and Marketing. The company is involved in the salmon feed production, salmon farming and primary processing, and seafood secondary processing activities. It offers whole gutted fish, including Label Rouge and organic salmon; and white fish and other seafood products, as well as fillets, steaks, cutlets, portions, loins, kebabs, and steak combos. The company also provides value added products, such as breaded, pre-fried, dusted, marinated, grilled, battered, topped, filled with sauce, delicatessen, fresh fish ready meal, and smoked fish products. It offers its products under the Mowi, Mowi Salmon, Donegal Silver, Admiral's, Pieters, Laschinger, Kritsen, Ducktrap River, Harbour Salmon Co., Rebel Fish, Supreme Salmon, Olav's, Northern Harvest, and Mowi Nutrition brand names. The company was formerly known as Marine Harvest ASA and changed its name to Mowi ASA in December 2018. Mowi ASA was founded in 1964 and is headquartered in Bergen, Norway.
Earnings Per Share
As for profitability, MOWI has a trailing twelve months EPS of kr8.63.
PE Ratio
MOWI has a trailing twelve months price to earnings ratio of 20.99. Meaning, the purchaser of the share is investing kr20.99 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.75%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Sep 1, 2023, the estimated forward annual dividend rate is 8 and the estimated forward annual dividend yield is 4.43%.
Yearly Top and Bottom Value
MOWI’s stock is valued at kr181.15 at 06:20 EST, way below its 52-week high of kr205.80 and way higher than its 52-week low of kr146.60.
Volume
Today’s last reported volume for MOWI is 274301 which is 62.57% below its average volume of 733001.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 16.3% and a negative 9.8%, respectively.
More news about MOWI.
4. MULTICONSULT (MULTI.OL)
10% sales growth and 29.75% return on equity
Multiconsult ASA provides engineering design, consultancy, and architecture services in Norway and internationally. The company offers multidisciplinary consultancy, design, planning, project supervision and management, geotechnical site survey, verification and control, analysis and due diligence, construction management, geological investigations, environmental services and HSE, river basin management, hydrometry, and hydrological field work services. It serves buildings and properties, cities and society, industry, oil and gas, renewable energy, rail and transportation, and water and environment sectors. Multiconsult ASA was founded in 1908 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MULTICONSULT has a trailing twelve months EPS of kr10.22.
PE Ratio
MULTICONSULT has a trailing twelve months price to earnings ratio of 11.94. Meaning, the purchaser of the share is investing kr11.94 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.75%.
More news about MULTICONSULT.
